Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer (Q35730375)

From Wikidata
Jump to navigation Jump to search
scientific article published on July 2008
edit
Language Label Description Also known as
English
Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer
scientific article published on July 2008

    Statements

    Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer (English)
    Thomas C Krivak
    Kathleen M Darcy
    Chunqiao Tian
    Deborah Armstrong
    Bora E Baysal
    Holly Gallion
    Julie A DeLoia
    Gynecologic Oncology Group Phase III Trial
    3598-3606

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit